• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    CEU Cardinal Herrera University,Centro de Estudios Universitarios

    院校EST. 1970
    2,251论文总数
    3.4万引用总数

    CEU Cardenal Herrera University (in Spanish: Universidad CEU Cardenal Herrera) is a private university located in the Valencian Community, Spain. It is part of the CEU Foundation, being the first private school of Law ever founded in Valencia. It has been associated to the University of Valencia and Polytechnic University of Valencia since the early 1970s but the University gained its current name in 1999.The University has five faculties:CEU UCH offers degrees in English (Bachelor's degrees in Architecture, Veterinary Medicine, Dentistry, Medicine, Pharmacy, Nursing Studies and Gastronomy and Culinary Management), in French (Médecine Vétérinaire) and in Spanish. It boasts three modern campuses in Alfara del Patriarca (12 km from Valencia), Elche (Alicante) and Castellón. CEU UCH currently provides high-quality teaching to over 9,250 students from all over the world, with 35% of its students being international.International rankings place CEU UCH at the top of the 23 Spanish private universities, rankings like Shanghai Jiao Tong University's Academic Ranking of World Universities (ARWU) placed CEU UCH the second Spanish private university, after the University of Navarra, in terms of research in 2013. In 2014 U-Multirank, a new global university ranking financed by the EU which assesses the performance of more than 850 higher education institutions worldwide, placed CEU-UCH as the tenth European university in agreement to regional involvement, scientific productivity and international orientation.

    论文量&引用量时间轴

    机构学者

    论文(2252)

    年份
    起
    –
    止
    排序
    1CX-Mind: A Pioneering Multimodal Large Language Model for Interleaved Reasoning in Chest X-ray Via Curriculum-Guided Reinforcement Learning
    Wenjie Li, Yujie Zhang, Haoran Sun, Yueqi Li,Fanrui Zhang, Mengzhe Xu, Victoria Borja Clausich, Sade Mellin,Renhao Yang, Chenrun Wang, Jethro Zih-Shuo Wang, Shiyi Yao,

    Chest X-ray (CXR) imaging is one of the most widely used diagnostic modalities in clinical practice, encompassing a broad spectrum of diagnostic tasks. Recent advancements have seen the extensive application of reasoning-based multimodal large language models (MLLMs) in medical imaging to enhance diagnostic efficiency and interpretability. However, existing multimodal models predominantly rely on ”one-time” diagnostic approaches, lacking verifiable supervision of the reasoning process. This leads to challenges in multi-task CXR diagnosis, including lengthy reasoning, sparse rewards, and frequent hallucinations. To address these issues, we propose CX-Mind, the first generative model to achieve interleaved ”think-answer” reasoning for CXR tasks, driven by curriculum-based reinforcement learning and verifiable process rewards (CuRL-VPR). Specifically, we constructed an instruction-tuning dataset, CX-Set, comprising 708,473 images and 2,619,148 samples, and generated 42,828 high-quality interleaved reasoning data points supervised by clinical reports. Optimization was conducted in two stages under the Group Relative Policy Optimization framework: initially stabilizing basic reasoning with closed-domain tasks, followed by transfer to open-domain diagnostics, incorporating rule-based conditional process rewards to bypass the need for pretrained reward models. Extensive experimental results demonstrate that CX-Mind significantly outperforms existing medical and general-domain MLLMs in visual understanding, text generation, and spatiotemporal alignment, achieving an average performance improvement of 25.1% over comparable CXR-specific models. On a real-world clinical dataset (Rui-CXR), CX-Mind achieves a mean recall@1 across 14 diseases that substantially surpasses the second-best results, with multi-center expert evaluations further confirming its clinical utility across multiple dimensions. CX-Mind establishes a new paradigm for constructing interpretable, and high-performing medical MLLMs.

    2026INFORMATION FUSION(2026)引用:6
    引用
    AI阅读
    加入学术空间
    2Effectiveness of Transcutaneous and Percutaneous Electrical Nerve Stimulation As Adjunct Therapies in Patients after Anterior Cruciate Ligament Reconstruction: Study Protocol for a Randomized Controlled Trial.
    Luis Blanco-López, Iván Nácher-Moltò,Juan Luis Sánchez-González, Daniel Casado-Gómez, Adrián Cases-Sebastià, Javier Reina-Abellán

    Background/Objectives: Quadriceps arthrogenic muscle inhibition (AMI) represents a key impairment following anterior cruciate ligament reconstruction (ACLR), contributing to quadriceps weakness. Although transcutaneous electrical nerve stimulation (TENS) and percutaneous electrical nerve stimulation (PENS) have been primarily investigated for analgesia, their effects on quadriceps strength in the early postoperative period remain underexplored. Methods: This study describes a single-blinded, parallel-group randomized controlled trial investigating the short-term effects of a single high-frequency TENS session and a novel long-term potentiation (LTP) PENS protocol on quadriceps strength and related clinical outcomes after ACLR. Fifty-four participants will be randomly allocated using block randomization in a 1:1:1 ratio to one of three groups: a control group (conventional post-ACLR rehabilitation only), a TENS group (conventional rehabilitation plus a single high-frequency TENS session), or a PENS group (conventional rehabilitation plus a single LTP PENS session). Participants will receive neuromodulatory intervention during the sixth postoperative week. The LTP PENS protocol consists of five 5 s stimulation bursts at 100 Hz and 250 μs pulse width and has only been investigated once in patients with upper limb pathology, underscoring its novelty in a postoperative setting. Results: The primary outcome is quadriceps maximal voluntary isometric contraction, selected as a clinically relevant surrogate of quadriceps activation deficits associated with AMI. Secondary outcomes include pain intensity, pressure pain threshold, knee range of motion, thigh muscle perimeter, knee effusion and swelling, and self-reported function and knee-related quality of life. Outcomes will be assessed at baseline, immediately post-treatment, and 1 and 7 days post-intervention by a blinded assessor.

    2026Journal of clinical medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Osseodensification Versus Standard Osteotomy: Systematic Review and Meta-Analysis of Dental Implant Torque and Stability.
    G Marzorati, F Khayyat, V Bermúdez, I Cortell, B Merck

    The aim of this study was to analyse and compare the biomechanical performance of a novel drilling technique known as osseodensification, which focuses on bone preservation and compaction rather than removal, against the conventional osteotomy technique in implant placement. Online databases were searched to identify relevant articles published in English during the last 10 years (up until September 11, 2025), reporting in vivo clinical trials involving a healthy adult population undergoing single or multiple implant placement, and comparing osseodensification and standard osteotomy drills, in a partially or fully edentulous segment of alveolar bone. Biomechanical measures analysed were the insertion torque and implant stability quotient (ISQ). Risk of bias and study quality were evaluated using the RoB 2 tool, Newcastle-Ottawa Scale, and GRADE system. The results were synthesized. Overall, a total of 555 patients (59.2% female, in studies reporting the sex distribution), received a total of 685 implants (343 using osseodensification). The overall mean insertion torque in the osseodensification group was 45.75 ± 6.55 N·cm, while in the standard osteotomy group it was 38.00 ± 7.01 N·cm (P < 0.001). The estimated average mean difference in ISQ (random-effects model) was 3.24 (95% confidence interval 0.72-5.95; P = 0.024). The data showed that sites prepared with osseodensification resulted in higher implant torque and primary stability of the implant (ISQ) immediately postoperative. However, longitudinal data were insufficient to allow a meaningful statistical analysis of ISQ trends over time.

    2026International journal of oral and maxillofacial surgery(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant (ela) Plus Everolimus (EVE) Versus Elacestrant Plus Placebo in ER+/HER2-advanced Breast Cancer (abc) Patients with ESR1-mutated Tumors Progressing on Endocrine Therapy (Et)+cdk4/6i.
    Antonio Llombart-Cussac,Jose Manuel Perez Garcia,Elena Lopez-Miranda,Cristina Saavedra,Vicente Caranana,Isabel Blancas, Carmen Hinojo Gonzalez,Alfonso Cortes-Salgado, Elena Galve Calvo, Rui, Daniel Alcala-Lopez, Juliana Carvalho Santos,

    TPS1129 Background: ET+CDK4/6i is standard-of-care (SOC) in 1L ER+/HER2- aBC; however, tumors eventually develop resistance. Constitutive activation in the PI3K/AKT/mTOR pathway can contribute to endocrine resistance in breast cancer. ESR1 mutations are a common type of acquired resistance that emerges in 40-50% of patients in the metastatic setting after prolonged aromatase inhibitor exposure. There is an unmet need for novel therapeutic approaches to overcome resistance mechanisms and improve outcomes in patients with ER+/HER2- aBC with ESR1 -mutated tumors progressing after ET+CDK4/6i. ELA is a next-generation oral SERD that binds to ER-alpha, inducing its degradation. In EMERALD, ELA improved PFS vs SOC ET in patients with ESR1 -mutated tumors (HR 0.55; 95% CI 0.39-0.77; P=0.0005) [Bidard 2022]. Differences were notable among patients who received prior ET+CDK4/6i ≥12 mo; median PFS with ELA was 8.6 mo vs 1.9 mo with SOC ET (HR 0.41; 95% CI 0.26-0.63) [Bardia 2024]. Crosstalk between ER and PI3K/AKT/mTOR pathways provides a rationale for evaluating ELA+EVE (a mTORC1 inhibitor). In ELEVATE phase 1b (NCT05563220), ELA+EVE demonstrated ORR 22% and CBR at 24 weeks 72% in patients with ER+/HER2- aBC progressing after ET+CDK4/6i; ELA 345 mg + EVE 7.5 mg was identified as the RP2D [Rugo ESMO 2024]. Safety was consistent with the known profile of EVE+SOC ET. ADELA compares ELA+EVE vs ELA+PBO in ER+/HER2- aBC patients with ESR1- mutated tumors progressing on ET+CDK4/6i. Methods: ADELA (NCT06382948) is an international, multicenter, double-blind, placebo-controlled phase 3 trial. Eligible patients are adults (≥18 yrs) with ER+/HER2- aBC and ESR1 -mutated tumors, previously treated with 1-2 lines of ET for aBC, and evidence of disease progression on prior ET+CDK4/6i for aBC after ≥6 mo. Patients receiving CDK4/6i-based adjuvant therapy are eligible (disease progression must be confirmed after ≥12 mo of treatment but <12 mo following CDK4/6i completion). Other criteria include adequate organ function and ECOG PS 0-1. Exclusion criteria include prior chemotherapy for aBC and active uncontrolled/symptomatic brain metastasis. Patients will be randomized 1:1 to 28-d cycles of ELA 345 mg + EVE 7.5 mg QD or ELA 345 mg + PBO QD until disease progression or unacceptable toxicity. Patients will receive dexamethasone mouthwash during the first 8 wks. Stratification factors are presence of visceral metastases (yes vs no) and duration of prior CDK4/6i (≥12 mo vs <12 mo). The primary objective will be to evaluate PFS based on blinded independent review committee. Secondary endpoints include investigator-assessed PFS, OS, ORR, CBR, DoR, TTR, best percentage change in tumor burden, safety, and HRQoL. Status: Planned enrollment is 240 patients; recruitment is ongoing. Clinical trial information: NCT06382948 .

    2026JOURNAL OF CLINICAL ONCOLOGY(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Por Qué El Ejercicio Es Un Aliado Eficaz Para Combatir Las Migrañas
    Miriam Garrigós
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2252 篇论文

    合作机构(100)

    瓦伦西亚大学合作论文 311
    瓦伦西亚理工大学合作论文 92
    阿利坎特大学合作论文 54
    马德里康普顿斯大学合作论文 51
    穆尔西亚大学合作论文 43
    巴塞罗那自治大学合作论文 34
    萨拉戈萨大学合作论文 25
    University of Las Palmas de Gran Canaria合作论文 25
    科尔多瓦大学合作论文 22
    Valencia Catholic University Saint Vincent Martyr合作论文 22

    机构统计